{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Ganfule capsule", "Molecular docking", "Multiple screening strategies", "Network analysis", "Non-alcoholic fatty liver disease", "Traditional herbal medicines"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": [], "OtherID": [], "GeneralNote": [], "PMID": "39113948", "DateRevised": {"Year": "2024", "Month": "08", "Day": "09"}, "Article": {"Language": ["eng"], "ELocationID": ["e34297", "10.1016/j.heliyon.2024.e34297"], "ArticleDate": [{"Year": "2024", "Month": "07", "Day": "10"}], "Journal": {"ISSN": "2405-8440", "JournalIssue": {"Volume": "10", "Issue": "14", "PubDate": {"Year": "2024", "Month": "Jul", "Day": "30"}}, "Title": "Heliyon", "ISOAbbreviation": "Heliyon"}, "ArticleTitle": "The molecular and network mechanisms of antilipidemic potential effects of Ganfule capsules in nonalcoholic fatty liver disease.", "Pagination": {"StartPage": "e34297", "MedlinePgn": "e34297"}, "Abstract": {"AbstractText": ["Non-alcoholic fatty liver disease (NAFLD) is a common liver disorder characterized by hepatic steatosis, inflammation and fibrosis. Ganfule (GFL), a traditional Chinese medicine, has demonstrated therapeutic potential in the treatment of NAFLD but the mechanisms involved are not fully understood.To evaluate the biochemical mechanisms of GFL in treating NAFLD by examining its effects on biological networks, key therapeutic targets, histopathological changes and clinical implications.", "Chemical component screening, key target prediction, biological functional enrichment analysis, lipid profile localization analysis and complex network analysis were performed on GFL using multi-database mining, network analysis and molecular docking. An NAFLD rat model was then established and treated with different doses of GFL. Histopathological evaluation and western blotting were used to verify the expression levels of key target proteins in GFL-treated NAFLD rats.", "Network analysis analysis identified 12 core targets, 12 core active ingredients and 7 core Chinese medicinal herbs in GFL potentially involved in the treatment of NAFLD. Biological functional enrichment analysis revealed the involvement of lipid metabolism, apoptosis and intracellular signaling pathways. Molecular docking confirmed a strong affinity between GFL's core compounds and certain target proteins. Histopathological examination of an NAFLD rat model showed reduced hepatocellular steatosis after GFL treatment. Western blotting revealed significant downregulation of PPARA and PPARD protein expression and upregulation of PIK3CG and PRKACA protein expression in NAFLD rats treated with lower doses of GFL.", "Our results suggest that GFL modulates key proteins involved in lipid metabolism and apoptosis pathways. GFL improved the histopathological features of NAFLD rats by regulating lipid metabolism as well as reducing hepatocyte apoptosis and hepatocellular steatosis. These findings offer insights into the biochemical mechanism of action of GFL and support its use in the treatment for NAFLD."], "CopyrightInformation": "\u00a9 2024 The Author(s)."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Guangxi Botanical Garden of Medicinal Plants, Nanning, 530023, Peoples Republic of China."}, {"Identifier": [], "Affiliation": "National Engineering Research Center of Southwest Endangered Medicinal Resource Development, Nanning, 530023, Peoples Republic of China."}], "LastName": "Pan", "ForeName": "Yu", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Guangxi Botanical Garden of Medicinal Plants, Nanning, 530023, Peoples Republic of China."}, {"Identifier": [], "Affiliation": "Chinese Medicinal Materials Product Quality Supervision and Inspection Station, 530023, Peoples Republic of China."}], "LastName": "Qiao", "ForeName": "Liya", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Hunan Engineering Technology Research Center for Bioactive Substance Discovery of Chinese Medicine, School of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410208, Peoples Republic of China."}, {"Identifier": [], "Affiliation": "Hunan Province Sino-US International Joint Research Center for Therapeutic Drugs of Senile Degenerative Diseases, Hunan University of Chinese Medicine, Changsha, 410208, Peoples Republic of China."}], "LastName": "Zhang", "ForeName": "Yunkun", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Academic Department of Obstetrics and Gvnaecology, Imperial College London, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW109NH, United Kingdom."}], "LastName": "Sooranna", "ForeName": "Suren R", "Initials": "SR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Guangxi Botanical Garden of Medicinal Plants, Nanning, 530023, Peoples Republic of China."}, {"Identifier": [], "Affiliation": "National Engineering Research Center of Southwest Endangered Medicinal Resource Development, Nanning, 530023, Peoples Republic of China."}], "LastName": "Huang", "ForeName": "Danna", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Guangxi Botanical Garden of Medicinal Plants, Nanning, 530023, Peoples Republic of China."}, {"Identifier": [], "Affiliation": "National Engineering Research Center of Southwest Endangered Medicinal Resource Development, Nanning, 530023, Peoples Republic of China."}], "LastName": "Ou", "ForeName": "Min", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Hunan Engineering Technology Research Center for Bioactive Substance Discovery of Chinese Medicine, School of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410208, Peoples Republic of China."}, {"Identifier": [], "Affiliation": "Hunan Province Sino-US International Joint Research Center for Therapeutic Drugs of Senile Degenerative Diseases, Hunan University of Chinese Medicine, Changsha, 410208, Peoples Republic of China."}], "LastName": "Xu", "ForeName": "Fei", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Guangxi Botanical Garden of Medicinal Plants, Nanning, 530023, Peoples Republic of China."}, {"Identifier": [], "Affiliation": "National Engineering Research Center of Southwest Endangered Medicinal Resource Development, Nanning, 530023, Peoples Republic of China."}], "LastName": "Chen", "ForeName": "Lu", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Hunan Engineering Technology Research Center for Bioactive Substance Discovery of Chinese Medicine, School of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410208, Peoples Republic of China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Chinese Medicine Powder and Medicine Innovation in Hunan (Incubation), Science and Technology Innovation Center, Hunan University of Chinese Medicine, Changsha, 410208, Peoples Republic of China."}], "LastName": "Huang", "ForeName": "Dan", "Initials": "D"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Heliyon", "NlmUniqueID": "101672560", "ISSNLinking": "2405-8440"}, "CoiStatement": "The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328\u2013357. doi: 10.1002/hep.29367.", "ArticleIdList": ["10.1002/hep.29367", "28714183"]}, {"Citation": "Younossi Z.M., Golabi P., de Avila L., et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J. Hepatol. 2019;71(4):793\u2013801. doi: 10.1016/j.jhep.2019.06.021.", "ArticleIdList": ["10.1016/j.jhep.2019.06.021", "31279902"]}, {"Citation": "Estes C., Anstee Q.M., Arias-Loste M.T., et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J. Hepatol. 2018;69(4):896\u2013904. doi: 10.1016/j.jhep.2018.05.036.", "ArticleIdList": ["10.1016/j.jhep.2018.05.036", "29886156"]}, {"Citation": "Younossi Z.M., Blissett D., Blissett R., et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577\u20131586. doi: 10.1002/hep.28785.", "ArticleIdList": ["10.1002/hep.28785", "27543837"]}, {"Citation": "Dai X., Feng J., Chen Y., et al. Traditional Chinese Medicine in nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Chin. Med. 2021;16(1):68. doi: 10.1186/s13020-021-00469-4. Published 2021 Aug 3.", "ArticleIdList": ["10.1186/s13020-021-00469-4", "PMC8330116", "34344394"]}, {"Citation": "Zhou H., Ma C., Wang C., Gong L., Zhang Y., Li Y. Research progress in use of traditional Chinese medicine monomer for treatment of non-alcoholic fatty liver disease. Eur. J. Pharmacol. 2021;898 doi: 10.1016/j.ejphar.2021.173976.", "ArticleIdList": ["10.1016/j.ejphar.2021.173976", "33639194"]}, {"Citation": "Chen M., Xie Y., Gong S., et al. Traditional Chinese medicine in the treatment of nonalcoholic steatohepatitis. Pharmacol. Res. 2021;172 doi: 10.1016/j.phrs.2021.105849.", "ArticleIdList": ["10.1016/j.phrs.2021.105849", "34450307"]}, {"Citation": "Xu Y., Guo W., Zhang C., et al. Herbal medicine in the treatment of non-alcoholic fatty liver diseases-efficacy, action mechanism, and clinical application. Front. Pharmacol. 2020;11:601. doi: 10.3389/fphar.2020.00601. Published 2020 May 12.", "ArticleIdList": ["10.3389/fphar.2020.00601", "PMC7235193", "32477116"]}, {"Citation": "Ke C., Gao J., Tu J., et al. Ganfule capsule alleviates bile duct ligation-induced liver fibrosis in mice by inhibiting glutamine metabolism. Front. Pharmacol. 2022;13 doi: 10.3389/fphar.2022.930785. Published 2022 Oct 7.", "ArticleIdList": ["10.3389/fphar.2022.930785", "PMC9585157", "36278176"]}, {"Citation": "Li K., Xiao K., Zhu S., Wang Y., Wang W. Chinese herbal medicine for primary liver cancer therapy: perspectives and challenges. Front. Pharmacol. 2022;13 doi: 10.3389/fphar.2022.889799. Published 2022 May 5.", "ArticleIdList": ["10.3389/fphar.2022.889799", "PMC9117702", "35600861"]}, {"Citation": "Xu F., Li H., Pan Y., et al. Effects of Ganfule capsule on microbial and metabolic profiles in anti-hepatocellular carcinoma. J. Appl. Microbiol. 2022;132(3):2280\u20132292. doi: 10.1111/jam.15307.", "ArticleIdList": ["10.1111/jam.15307", "34564943"]}, {"Citation": "Fei X.U., Pan Yu, Han-ying L.I., et al. Identification of chemical constituents in Ganfule by UPLC-Q-TOF/MS combined with UNIFI software. Chin J Pharm Anal (\u836f\u7269\u5206\u6790\u6742\u5fd7) 2021;41(5):760\u2013778. doi: 10.16155/j.0254-1793.2021.05.03.", "ArticleIdList": ["10.16155/j.0254-1793.2021.05.03"]}, {"Citation": "Hopkins A.L. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 2008;4(11):682\u2013690. doi: 10.1038/nchembio.118.", "ArticleIdList": ["10.1038/nchembio.118", "18936753"]}, {"Citation": "Nogales C., Mamdouh Z.M., List M., Kiel C., Casas A.I., Schmidt H.H.H.W. Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends Pharmacol. Sci. 2022;43(2):136\u2013150. doi: 10.1016/j.tips.2021.11.004.", "ArticleIdList": ["10.1016/j.tips.2021.11.004", "34895945"]}, {"Citation": "Pinzi L., Rastelli G. Molecular docking: shifting paradigms in drug discovery. Int. J. Mol. Sci. 2019;20(18):4331. doi: 10.3390/ijms20184331. Published 2019 Sep. 4.", "ArticleIdList": ["10.3390/ijms20184331", "PMC6769923", "31487867"]}, {"Citation": "Wang X., Shen Y., Wang S., et al. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 2017;45(W1):W356\u2013W360. doi: 10.1093/nar/gkx374.", "ArticleIdList": ["10.1093/nar/gkx374", "PMC5793840", "28472422"]}, {"Citation": "Xu H., Zhang Y., Wang P., et al. A comprehensive review of integrative pharmacology-based investigation: a paradigm shift in traditional Chinese medicine. Acta Pharm. Sin. B. 2021;11(6):1379\u20131399. doi: 10.1016/j.apsb.2021.03.024.", "ArticleIdList": ["10.1016/j.apsb.2021.03.024", "PMC8245857", "34221858"]}, {"Citation": "Kalhori F., Yazdyani H., Khademorezaeian F., et al. Enzyme activity inhibition properties of new cellulose nanocrystals from Citrus medica L. pericarp: a perspective of cholesterol lowering. Luminescence. 2022;37(11):1836\u20131845. doi: 10.1002/bio.4360.", "ArticleIdList": ["10.1002/bio.4360", "35946171"]}, {"Citation": "Sharifi-Rad A., Mehrzad J., Darroudi M., Saberi M.R., Chamani J. Oil-in-water nanoemulsions comprising Berberine in olive oil: biological activities, binding mechanisms to human serum albumin or holo-transferrin and QMMD simulations. J. Biomol. Struct. Dyn. 2021;39(3):1029\u20131043. doi: 10.1080/07391102.2020.1724568.", "ArticleIdList": ["10.1080/07391102.2020.1724568", "32000592"]}, {"Citation": "Heinzelmann G., Gilson M.K. Automation of absolute protein-ligand binding free energy calculations for docking refinement and compound evaluation. Sci. Rep. 2021;11(1):1116. doi: 10.1038/s41598-020-80769-1. Published 2021 Jan 13.", "ArticleIdList": ["10.1038/s41598-020-80769-1", "PMC7806944", "33441879"]}, {"Citation": "Byrne C.D., Targher G. NAFLD: a multisystem disease. J. Hepatol. 2015;62(1 Suppl):S47\u2013S64. doi: 10.1016/j.jhep.2014.12.012.", "ArticleIdList": ["10.1016/j.jhep.2014.12.012", "25920090"]}, {"Citation": "Liu Y., Yang S., Wang K., et al. Cellular senescence and cancer: focusing on traditional Chinese medicine and natural products. Cell Prolif. 2020;53(10) doi: 10.1111/cpr.12894.", "ArticleIdList": ["10.1111/cpr.12894", "PMC7574878", "32881115"]}, {"Citation": "Li H. Advances in anti hepatic fibrotic therapy with Traditional Chinese Medicine herbal formula. J. Ethnopharmacol. 2020;251 doi: 10.1016/j.jep.2019.112442.", "ArticleIdList": ["10.1016/j.jep.2019.112442", "31891799"]}, {"Citation": "Yao H., Qiao Y.J., Zhao Y.L., et al. Herbal medicines and nonalcoholic fatty liver disease. World J. Gastroenterol. 2016;22(30):6890\u20136905. doi: 10.3748/wjg.v22.i30.6890.", "ArticleIdList": ["10.3748/wjg.v22.i30.6890", "PMC4974587", "27570425"]}, {"Citation": "Kasprzak-Drozd K., Oniszczuk T., Stasiak M., Oniszczuk A. Beneficial effects of phenolic compounds on gut microbiota and metabolic syndrome. Int. J. Mol. Sci. 2021;22(7):3715. doi: 10.3390/ijms22073715. Published 2021 Apr 2.", "ArticleIdList": ["10.3390/ijms22073715", "PMC8038165", "33918284"]}, {"Citation": "Wang Q., Ou Y., Hu G., et al. Naringenin attenuates non-alcoholic fatty liver disease by down-regulating the NLRP3/NF-\u03baB pathway in mice. Br. J. Pharmacol. 2020;177(8):1806\u20131821. doi: 10.1111/bph.14938.", "ArticleIdList": ["10.1111/bph.14938", "PMC7070172", "31758699"]}, {"Citation": "Imran M., Rauf A., Abu-Izneid T., et al. Luteolin, a flavonoid, as an anticancer agent: a review [published correction appears in Biomed Pharmacother. 2019 Aug;116:109084] Biomed. Pharmacother. 2019;112 doi: 10.1016/j.biopha.2019.108612.", "ArticleIdList": ["10.1016/j.biopha.2019.108612", "31178263"]}, {"Citation": "Dong L., Du H., Zhang M., et al. Anti-inflammatory effect of Rhein on ulcerative colitis via inhibiting PI3K/Akt/mTOR signaling pathway and regulating gut microbiota. Phytother Res. 2022;36(5):2081\u20132094. doi: 10.1002/ptr.7429.", "ArticleIdList": ["10.1002/ptr.7429", "35229916"]}, {"Citation": "Li X., Hu X., Pan T., et al. Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway. Biomed. Pharmacother. 2021;133 doi: 10.1016/j.biopha.2020.110802.", "ArticleIdList": ["10.1016/j.biopha.2020.110802", "33202286"]}, {"Citation": "Wang W., Xu A.L., Li Z.C., et al. Combination of probiotics and salvia miltiorrhiza polysaccharide alleviates hepatic steatosis via gut microbiota modulation and insulin resistance improvement in high fat-induced NAFLD mice. Diabetes Metab. J. 2020;44(2):336\u2013348. doi: 10.4093/dmj.2019.0042.", "ArticleIdList": ["10.4093/dmj.2019.0042", "PMC7188963", "31950772"]}, {"Citation": "Ye H., Ma S., Qiu Z., et al. Poria cocos polysaccharides rescue pyroptosis-driven gut vascular barrier disruption in order to alleviates non-alcoholic steatohepatitis. J. Ethnopharmacol. 2022;296 doi: 10.1016/j.jep.2022.115457.", "ArticleIdList": ["10.1016/j.jep.2022.115457", "35753609"]}, {"Citation": "Ye H., Ma S., Qiu Z., et al. Poria cocos polysaccharides rescue pyroptosis-driven gut vascular barrier disruption in order to alleviates non-alcoholic steatohepatitis. J. Ethnopharmacol. 2022;296 doi: 10.1016/j.jep.2022.115457.", "ArticleIdList": ["10.1016/j.jep.2022.115457", "35753609"]}, {"Citation": "Lei S., Zhao S., Huang X., et al. Chaihu Shugan powder alleviates liver inflammation and hepatic steatosis in NAFLD mice: a network pharmacology study and in vivo experimental validation. Front. Pharmacol. 2022;13 doi: 10.3389/fphar.2022.967623. Published 2022 Sep. 12.", "ArticleIdList": ["10.3389/fphar.2022.967623", "PMC9512055", "36172180"]}, {"Citation": "Zhang Y., Tang K., Deng Y., et al. Effects of shenling baizhu powder herbal formula on intestinal microbiota in high-fat diet-induced NAFLD rats. Biomed. Pharmacother. 2018;102:1025\u20131036. doi: 10.1016/j.biopha.2018.03.158.", "ArticleIdList": ["10.1016/j.biopha.2018.03.158", "29710519"]}, {"Citation": "Cai F.F., Bian Y.Q., Wu R., et al. Yinchenhao decoction suppresses rat liver fibrosis involved in an apoptosis regulation mechanism based on network pharmacology and transcriptomic analysis. Biomed. Pharmacother. 2019;114 doi: 10.1016/j.biopha.2019.108863.", "ArticleIdList": ["10.1016/j.biopha.2019.108863", "30991286"]}, {"Citation": "Zhang X., Zhang Z., Wang P., et al. Bawei Chenxiang wan ameliorates cardiac hypertrophy by activating AMPK/PPAR-\u03b1 signaling pathway improving energy metabolism. Front. Pharmacol. 2021;12 doi: 10.3389/fphar.2021.653901. Published 2021 Jun 3.", "ArticleIdList": ["10.3389/fphar.2021.653901", "PMC8209424", "34149410"]}, {"Citation": "Zhao G., Yang L., Zhong W., et al. Polydatin, A glycoside of resveratrol, is better than resveratrol in alleviating non-alcoholic fatty liver disease in mice fed a high-fructose diet. Front. Nutr. 2022;9 doi: 10.3389/fnut.2022.857879. Published 2022 May 16.", "ArticleIdList": ["10.3389/fnut.2022.857879", "PMC9149290", "35651514"]}, {"Citation": "Saraswathi V., Kumar N., Gopal T., et al. Lauric acid versus palmitic acid: effects on adipose tissue inflammation, insulin resistance, and non-alcoholic fatty liver disease in obesity. Biology. 2020;9(11):346. doi: 10.3390/biology9110346. Published 2020 Oct 22.", "ArticleIdList": ["10.3390/biology9110346", "PMC7690582", "33105887"]}, {"Citation": "Ulanowska M., Olas B. Biological properties and prospects for the application of eugenol-A review. Int. J. Mol. Sci. 2021;22(7):3671. doi: 10.3390/ijms22073671. Published 2021 Apr 1.", "ArticleIdList": ["10.3390/ijms22073671", "PMC8036490", "33916044"]}, {"Citation": "Chen J., Fan X., Zhou L., Gao X. Treatment with geraniol ameliorates methionine-choline-deficient diet-induced non-alcoholic steatohepatitis in rats. J. Gastroenterol. Hepatol. 2016;31(7):1357\u20131365. doi: 10.1111/jgh.13272.", "ArticleIdList": ["10.1111/jgh.13272", "26695085"]}, {"Citation": "Zhang X., Huo Z., Luan H., et al. Scutellarin ameliorates hepatic lipid accumulation by enhancing autophagy and suppressing IRE1\u03b1/XBP1 pathway. Phytother Res. 2022;36(1):433\u2013447. doi: 10.1002/ptr.7344.", "ArticleIdList": ["10.1002/ptr.7344", "34859513"]}, {"Citation": "Li Q., Tan J.X., He Y., et al. Atractylenolide III ameliorates non-alcoholic fatty liver disease by activating hepatic adiponectin receptor 1-mediated AMPK pathway. Int. J. Biol. Sci. 2022;18(4):1594\u20131611. doi: 10.7150/ijbs.68873. Published 2022 Jan 31.", "ArticleIdList": ["10.7150/ijbs.68873", "PMC8898375", "35280674"]}, {"Citation": "Shabbir U., Rubab M., Daliri E.B., Chelliah R., Javed A., Oh D.H. Curcumin, quercetin, catechins and metabolic diseases: the role of gut microbiota. Nutrients. 2021;13(1):206. doi: 10.3390/nu13010206. Published 2021 Jan 12.", "ArticleIdList": ["10.3390/nu13010206", "PMC7828240", "33445760"]}, {"Citation": "Dimitrov A.S. Methods in molecular biology. Therapeutic antibodies. Methods and protocols. Preface. Methods Mol. Biol. 2009;525 doi: 10.1007/978-1-59745-554-1. vii-xiii.", "ArticleIdList": ["10.1007/978-1-59745-554-1", "19350746"]}, {"Citation": "Chen D., Oezguen N., Urvil P., Ferguson C., Dann S.M., Savidge T.C. Regulation of protein-ligand binding affinity by hydrogen bond pairing. Sci. Adv. 2016;2(3) doi: 10.1126/sciadv.1501240. Published 2016 Mar 25.", "ArticleIdList": ["10.1126/sciadv.1501240", "PMC4820369", "27051863"]}, {"Citation": "Liang Z., Li Q.X. \u03c0-Cation interactions in molecular recognition: perspectives on pharmaceuticals and pesticides. J. Agric. Food Chem. 2018;66(13):3315\u20133323. doi: 10.1021/acs.jafc.8b00758.", "ArticleIdList": ["10.1021/acs.jafc.8b00758", "PMC7357627", "29522678"]}, {"Citation": "Yan T., Luo Y., Yan N., et al. Intestinal peroxisome proliferator-activated receptor \u03b1-fatty acid-binding protein 1 axis modulates nonalcoholic steatohepatitis. Hepatology. 2023;77(1):239\u2013255. doi: 10.1002/hep.32538.", "ArticleIdList": ["10.1002/hep.32538", "PMC9970020", "35460276"]}, {"Citation": "Pawlak M., Lefebvre P., Staels B. Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J. Hepatol. 2015;62(3):720\u2013733. doi: 10.1016/j.jhep.2014.10.039.", "ArticleIdList": ["10.1016/j.jhep.2014.10.039", "25450203"]}, {"Citation": "Zarei M., Aguilar-Recarte D., Palomer X., V\u00e1zquez-Carrera M. Revealing the role of peroxisome proliferator-activated receptor \u03b2/\u03b4 in nonalcoholic fatty liver disease. Metabolism. 2021;114 doi: 10.1016/j.metabol.2020.154342.", "ArticleIdList": ["10.1016/j.metabol.2020.154342", "32810487"]}, {"Citation": "Zhang W., Liu Y., Wu M., et al. PI3K inhibition protects mice from NAFLD by down-regulating CMKLR1 and NLRP3 in Kupffer cells. J. Physiol. Biochem. 2017;73(4):583\u2013594. doi: 10.1007/s13105-017-0589-6.", "ArticleIdList": ["10.1007/s13105-017-0589-6", "28905319"]}, {"Citation": "Wymann M.P., Solinas G. Inhibition of phosphoinositide 3-kinase \u03b3 attenuates inflammation, obesity, and cardiovascular risk factors. Ann. N. Y. Acad. Sci. 2013;1280:44\u201347. doi: 10.1111/nyas.12037.", "ArticleIdList": ["10.1111/nyas.12037", "23551103"]}, {"Citation": "Ko E., Seo H.W., Jung E.S., et al. PI3K\u03b4 is a therapeutic target in hepatocellular carcinoma. Hepatology. 2018;68(6):2285\u20132300. doi: 10.1002/hep.30307.", "ArticleIdList": ["10.1002/hep.30307", "30300952"]}, {"Citation": "Reid Lola, Sethupathy Praveen. The DNAJB1\u2010PRKACA chimera: candidate biomarker and therapeutic target for fibrolamellar carcinomas. Hepatology. February 2016;63(2):662\u2013664. doi: 10.1002/hep.28307.", "ArticleIdList": ["10.1002/hep.28307", "26505878"]}, {"Citation": "Gao S., Tan H., Li D. Oridonin suppresses gastric cancer SGC-7901 cell proliferation by targeting the TNF-alpha/androgen receptor/TGF-beta signalling pathway axis. J. Cell Mol. Med. 2023 Sep;27(18):2661\u20132674. doi: 10.1111/jcmm.17841. Epub 2023 Jul 11. PMID: 37431884; PMCID: PMC10494293.", "ArticleIdList": ["10.1111/jcmm.17841", "PMC10494293", "37431884"]}, {"Citation": "Gao S., Gang J., Yu M., Xin G., Tan H. Computational analysis for identification of early diagnostic biomarkers and prognostic biomarkers of liver cancer based on GEO and TCGA databases and studies on pathways and biological functions affecting the survival time of liver cancer. BMC Cancer. 2021 Jul 8;21(1):791. doi: 10.1186/s12885-021-08520-1. PMID: 34238253; PMCID: PMC8268589.", "ArticleIdList": ["10.1186/s12885-021-08520-1", "PMC8268589", "34238253"]}, {"Citation": "Huang D.Q., El-Serag H.B., Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 2021;18:223\u2013238. doi: 10.1038/s41575-020-00381-6.", "ArticleIdList": ["10.1038/s41575-020-00381-6", "PMC8016738", "33349658"]}, {"Citation": "Kaffash M., Tolou-Shikhzadeh-Yazdi S., Soleimani S., Hoseinpoor S., Saberi M.R., Chamani J. Spectroscopy and molecular simulation on the interaction of Nano-Kaempferol prepared by oil-in-water with two carrier proteins: an investigation of protein-protein interaction. Spectrochim. Acta Mol. Biomol. Spectrosc. 2024;309 doi: 10.1016/j.saa.2023.123815.", "ArticleIdList": ["10.1016/j.saa.2023.123815", "38154302"]}, {"Citation": "Hamid Maheri, Hashemzadeh Fatemeh, Shakibapour Niloofar, Kamelniya Elahe, Malaekeh-Nikouei Bizhan, Mokaberi Parisa, Chamani Jamshidkhan. Glucokinase activity enhancement by cellulose nanocrystals isolated from jujube seed: a novel perspective for type II diabetes mellitus treatment (In vitro) J. Mol. Struct. 2022;1269 doi: 10.1016/j.molstruc.2022.133803.", "ArticleIdList": ["10.1016/j.molstruc.2022.133803"]}]}], "History": [{"Year": "2024", "Month": "3", "Day": "27"}, {"Year": "2024", "Month": "7", "Day": "3"}, {"Year": "2024", "Month": "7", "Day": "8"}, {"Year": "2024", "Month": "8", "Day": "8", "Hour": "6", "Minute": "43"}, {"Year": "2024", "Month": "8", "Day": "8", "Hour": "6", "Minute": "42"}, {"Year": "2024", "Month": "8", "Day": "8", "Hour": "4", "Minute": "28"}, {"Year": "2024", "Month": "7", "Day": "10"}], "PublicationStatus": "epublish", "ArticleIdList": ["39113948", "PMC11305243", "10.1016/j.heliyon.2024.e34297", "S2405-8440(24)10328-3"]}}]}